OR and ICU Teams ‘Running In Parallel’ at the End of Cardiothoracic Surgery Improves Perceptions of Handoff Safety

For now—and possibly the next 18 to 24 months, convalescent plasma, despite supply issues and questions about efficacy and who is most likely to benefit from treatment, remains the only off-the-shelf therapy for COVID-19.